Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eyeing Agility, Astellas Expands Digital Transformation Initiative

Executive Summary

Soon-to-start digital transformation initiatives at the major Japanese pharma firm will focus on in-housing of IT systems and company-wide enhancement of AI/data analytics skills.

You may also be interested in...



Pfizer’s Super Bowl Commercial Departs From Drug Ad Format

In its first corporate Super Bowl ad, Pfizer celebrates history of scientific discoveries while promoting its cancer research. Astellas airs pre-game commercial for menopausal drug Veozah.

Japan Q3 Roundup: Majors Enjoy Forex Windfall But COVID Returns Decline

While the weaker yen boosted the top line for Japanese pharma companies with a strong global presence in the fiscal first half, it also raised reported costs. Several firms reported strong growth for mainstays, while holding out high hopes for selected new drugs with blockbuster potential. But some other products underperformed for unexpected reasons.

Takeda’s Weber On Digitalizing Pharma In Ongoing Strategic Shift

The entire pharmaceutical industry will transform itself with digital technology while still facing the challenge of financial balance as a part of the healthcare ecosystem, says Takeda's CEO, who shared his views on the firm’s and wider industry's shifting business and R&D strategies at the recent CPHI Japan meeting.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC149854

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel